Michael Barbella, Managing Editor03.11.24
In Japan, the number of patients with aortic valve stenosis has been growing due to the country's aging population. As a result, Japan's transcatheter aortic valve replacement (TAVR) market is expected to reach $820 million in 2033, according to GlobalData.
The company’s latest report, “Transcatheter Aortic Valve Replacement Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033” reveals that Japan’s TAVR market accounted for about 55% of the Asia-Pacific (APAC) market last year.
“The increasing prevalence of aortic stenosis among the aging population, new device approvals, and patient preference for minimally-invasive procedures are some of the factors driving the TAVR market in Japan," GlobalData Medical Devices Analyst Nandini Nagpal said. "As the conventional TAVR procedure is complex due to its intricate nature, accessibility is limited, which highlights the need for more innovation in the market.”
In a major development for the TAVR market, Japan Lifeline Co. Ltd. signed an agreement with Indian medical device company Meril Life Sciences Pvt. Ltd. in October 2023 to gain exclusive rights to introduce Meril’s Myval Octacor, a transcatheter heart valve, in Japan (it received approval from the Japanese Pharmaceuticals and Medical Devices Agency). Myval Octacor is a balloon-expandable implant specifically created for TAVR/TAVI procedures. This artificial heart valve features various sizes to accommodate a wide range of patients and comes with an octagonal cell structure intended to enhance the precision of placement.
“Innovations in this space will likely lead to more advanced, versatile, and durable devices that enable minimally invasive procedures for aortic valve stenosis with greater accuracy and fewer complications. Considering that Meril has successfully implanted more than 25,000 such heart valves in 75 countries around the world, Myval Octacor is expected to be successful in the Japanese cardiovascular market after its launch,” Nagpal concluded.
The company’s latest report, “Transcatheter Aortic Valve Replacement Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033” reveals that Japan’s TAVR market accounted for about 55% of the Asia-Pacific (APAC) market last year.
“The increasing prevalence of aortic stenosis among the aging population, new device approvals, and patient preference for minimally-invasive procedures are some of the factors driving the TAVR market in Japan," GlobalData Medical Devices Analyst Nandini Nagpal said. "As the conventional TAVR procedure is complex due to its intricate nature, accessibility is limited, which highlights the need for more innovation in the market.”
In a major development for the TAVR market, Japan Lifeline Co. Ltd. signed an agreement with Indian medical device company Meril Life Sciences Pvt. Ltd. in October 2023 to gain exclusive rights to introduce Meril’s Myval Octacor, a transcatheter heart valve, in Japan (it received approval from the Japanese Pharmaceuticals and Medical Devices Agency). Myval Octacor is a balloon-expandable implant specifically created for TAVR/TAVI procedures. This artificial heart valve features various sizes to accommodate a wide range of patients and comes with an octagonal cell structure intended to enhance the precision of placement.
“Innovations in this space will likely lead to more advanced, versatile, and durable devices that enable minimally invasive procedures for aortic valve stenosis with greater accuracy and fewer complications. Considering that Meril has successfully implanted more than 25,000 such heart valves in 75 countries around the world, Myval Octacor is expected to be successful in the Japanese cardiovascular market after its launch,” Nagpal concluded.